23rd Annual Psychopharmacology Update

Friday, October 25, 2024, 7:15 AM - Saturday, October 26, 2024, 4:30 PM, Hyatt Regency Cincinnati, 151 W. 5th Street, Cincinnati, OH

AMA PRA Category 1 Credits™ (12.50 hours), AMA PRA Category 1 Credits™ Designated (12.50 hours)


The Annual Psychopharmacology Update is a 2-day in-person conference held October 25-26, 2024, presenting in-depth workshops and advanced educational Masterclass sessions with interactive audience Q&A and polling.  Day One of the conference features CME-certified workshops as well as a special Keynote Speaker. On Day Two, our nationally renowned faculty will present a Masterclass series providing a deep-dive into the evidence on novel and emerging pharmacotherapies and treatment paradigms addressing important clinical challenges facing psychiatry clinicians. 

1. Assess the physiologic function of novel receptors in the brain and their role as potential therapeutic targets.
2. Apply knowledge of pathophysiologic basis of agitation associated with Alzheimer's disease
3. Describe the mechanism of action of pharmacotherapies studied for the management of agitation associated with Alzheimer’s disease.
4. Demonstrate greater confidence related to understanding the Modes of Action of emerging treatments for Schizophrenia, Bipolar Disorder, Mood, and Psychotic Disorders.
5. Compare clinical data on the efficacy and safety of emerging psychotropic agents across psychiatric conditions.
6. Explain latest clinical data and emerging ADHD treatments for both adult and pediatric populations.
7. Recognize where novel psychotropic agents may fit into the treatment paradigm for patients with Schizophrenia and Bipolar Disorder, Mood, and Psychotic Disorders.
8. Assess the efficacy and safety of current pharmacotherapies for delirium and dementia, including medication combinations and adjunctive therapies.
9. Recognize the risk of treatment non-response and relapse in patients with Schizophrenia, Bipolar Disorder, Mood, and Psychotic Disorders.
10. Discuss current definitions, criteria, and recent guidelines for treatment resistance in various psychiatric disorders.
11. Evaluate therapeutic options for patients who have an inadequate response to treatment, including the use of combination and augmentation therapies.
12. Develop individualized treatment plans for neuropsychiatric disorders using personalized medicine strategies.
13. Incorporate novel approaches to the clinical management of complex psychiatric disorders.
14. Review factors that impact the emergence of adverse effects of psychotropic drugs.
15. Evaluate strategies to monitor for and manage adverse effects to improve patient adherence and optimize clinical outcomes.
16. Recognize where emerging therapies with novel MOAs may fit into future treatment strategies for adult and pediatric populations living with ADHD.

Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education (GAME). The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Cincinnati designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

Hyatt Regency Cincinnati
151 W. 5th Street
Cincinnati, OH 45202
(513) 579-1234

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

No faculty are available for this activity at this time.